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pandemic has led to surges of patients presenting to emergency
departments (EDs) and potentially overwhelming health
systems.
Objective: We sought to assess the predictive accuracy of host
biomarkers at clinical presentation to the ED for adverse
outcome.
Methods: Prospective observational study of PCR-confirmed
COVID-19 patients in the ED of a Swiss hospital.
Concentrations of inflammatory and endothelial dysfunction
biomarkers were determined at clinical presentation. We
evaluated the accuracy of clinical signs and these biomarkers in
predicting 30-day intubation/mortality, and oxygen requirement
by calculating the area under the receiver-operating
characteristic curve and by classification and regression tree
analysis.
Results: Of 76 included patients with COVID-19, 24 were
outpatients or hospitalized without oxygen requirement, 35
hospitalized with oxygen requirement, and 17 intubated/died.
We found that soluble triggering receptor expressed on
myeloid cells had the best prognostic accuracy for 30-day
intubation/mortality (area under the receiver-operating
characteristic curve, 0.86; 95% CI, 0.77-0.95) and IL-6
measured at presentation to the ED had the best accuracy for
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https://doi.org/10.1016/j.jaci.2020.10.001characteristic curve, 0.84; 95% CI, 0.74-0.94). An algorithm
based on respiratory rate and sTREM-1 predicted 30-day
intubation/mortality with 94% sensitivity and 0.1 negative
likelihood ratio. An IL-6–based algorithm had 98% sensitivity
and 0.04 negative likelihood ratio for 30-day oxygen
requirement.
Conclusions: sTREM-1 and IL-6 concentrations in COVID-19
in the ED have good predictive accuracy for intubation/
mortality and oxygen requirement. sTREM-1– and IL-6–based
algorithms are highly sensitive to identify patients with adverse
outcome and could serve as early triage tools. (J Allergy Clin
Immunol 2021;147:99-106.)
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The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pandemic has led to surges of patients that can
overwhelm health systems.1-4 Medical resource constraints and
scarcity are a new reality including lack of hospital beds, oxygen
concentrators, and ventilators in both high- and low-income
countries.5,6 There is an urgent need to have guidance
allowing the rational allocation of scarce medical equipment
and resources. In this context, it is critical to have triage tools
in place permitting the early recognition of patients at risk of
adverse outcomes, and allow for optimal resource allocation.7-9
Current prediction models to support clinical decision making
for patients with coronavirus disease 2019 (COVID-19) were
developed on the basis of demographic characteristics, clinical
signs and symptoms, imaging techniques, biomarkers, or a com-
bination of these variables; however, most are poorly validated
and at risk of bias.10
Cytokine dysregulation during COVID-19 is suspected to
contribute to disease severity, and multiple clinical trials are
underway to test the efficacy of immunomodulatory thera-
pies.11-13 A recent study identified different inflammatory cyto-
kine profiles according to the stage of the disease, suggesting
their usefulness for risk stratification in patients with
COVID-19.13 IL-6, IL-8, and C-reactive protein (CRP) have
been proposed for monitoring and prognosis purpose in the
context of COVID-19.14-16 Triggering receptor expressed on
myeloid cells (TREM-1) is a receptor expressed both on the sur-
face of blood neutrophils and onmaturemonocytes/macrophages,
which have been implicated in severe COVID-19.17-19 Soluble
TREM-1 (sTREM-1) is its cleaved soluble circulating counter-
part. As previously shown, sTREM-1 has a prognostic value in
septic shock and other infectious states but has never been studied
in the context of COVID-19.20-22 Furthermore, endothelial cell
infection and dysfunction might explain systemic impaired
microcirculatory and multiorgan dysfunction with onset of99
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this contention, several studies have reported an association be-
tween markers of a procoagulable state (eg, D-dimers and fibrin-
ogen) and patients outcome.25-27 In a French study, level of
angiopoietin-2 (Ang-2) as marker of endothelial activation pre-
dicted with a medium accuracy the intensive care unit admission
for COVID-19.28
Here, we investigate the predictive accuracy of a panel of host
markers of inflammatory and endothelial dysfunction in patients
with COVID-19 at presentation to the emergency department
(ED), for 30-day intubation/mortality, as well as for 7-day
intubation/mortality and 7- and 30-day oxygen requirement. We
also evaluate the predictive value of biomarkers in combination
with clinical signs and validated clinical severity scores.METHODS
Study design and participants
This prospective observational cohort study of patients with COVID-19
was conducted in the ED of Lausanne University Hospital (CHUV), a tertiary
care center in Switzerland. We prospectively screened all patients (age >_ 18
years) upon arrival at the EDwith symptoms of an acute lower respiratory tract
infection (cough, sputum, dyspnea, or chest pain for <21 days) between
February 6, 2020, and April 3, 2020.29 Patients were included in this study if
COVID-19 was confirmed by reverse transcription PCR for SARS-CoV-2
from a nasopharyngeal swab.
Patients’ demographic characteristics, comorbidities, symptoms, vital
signs, and laboratory test results performed during routine care were recorded
in the ED using a standardized electronic case report form in Research
Electronic Data Capture. Easy-to-measure bedside clinical scores to identify
patients at risk of poor outcome were calculated at inclusion: (1) quick
Sequential Organ Failure Assessment (qSOFA): 1 point each for systolic
hypotension (<_100 mm Hg), tachypnea (>_22/min), or altered mentation
(Glasgow Coma Scale score <_14),30 (2) CRB-65: 1 point each for confusion
(Glasgow Coma Scale score <_14), elevated respiratory rate (>_30/min), low
blood pressure (systolic <90 mm Hg or diastolic <_60 mm Hg), age 65 years
or more.31 Clinical outcomes on days 7 and 30 were assessed by checking
the electronic health record and by calling patients.
Patients were classified into 2 groups according to COVID-19 severity: (1)
outpatients and/or admission without oxygen requirement within 30 days of
presentation, (2) hospital admission and oxygen requirement without
intubation and/or death, and (2) intubation and/or death.Host biomarkers of endothelial and immune
dysfunction
A plasma sample was collected in the ED at enrollment and stored at
2808C without freeze-thaw until analysis. Plasma concentrations of endo-
thelial and immune mediators (Ang-2, IL-6, IL-8, and sTREM-1) were
analyzed head-to-head on a multianalyte Ella platform with custom-developed reagents from Protein Simple (San Jose, Calif) as described.32
CRP was quantified by ELISAs (R&D DuoSet, Minneapolis, Minn).Statistical analyses
Differences between the 3 groups were evaluated by 1-way ANOVA,
Kruskal-Wallis, or chi-square test, as appropriate. A bilateral P value of less
than .05 was considered indicative of statistical significance.
The primary outcome was 30-day intubation/mortality. Secondary out-
comes were 7-day intubation/mortality and 7- and 30-day oxygen requirement
(all patients hospitalized with oxygen requirement, including those who were
intubated or died, as they all received oxygen).
These outcomes are important for pragmatic clinical decision making in
the ED. They are objective and therefore more reproducible in other settings
than clinician decision to admit a patient to hospital or to the intensive care
unit. We hypothesized first, that patients intubated or fatal within 30 days of
the ED consultation absolutely require hospital admission and close
monitoring and, second, that patients requiring oxygen supplementation
within 30 days need close medical follow-up as outpatient or in-patient
depending on health care resources.5 The diagnostic accuracy of clinical
signs, clinical severity scores, and host biomarkers to predict intubation/
death and oxygen requirement was assessed by calculating the area under
the receiver-operating characteristic curve (AUROC). Biomarkers with
excellent discrimination value (AUROC >_ 0.80) as well as vital signs and
clinical severity scores were selected for the multivariate analysis.33 The
linearity of the continuous variables with respect to the logit of the depen-
dent variable was assessed via the Box-Tidwell procedure and by inspecting
the partial residuals. Nonlinear variables were transformed for multivariate
logistic regression. The predictive validity of a combinatorial model adding
top biomarkers to vital signs or clinical severity scores was measured using
logistic regression, and the predicted probabilities were used to generate
AUROC. The combinatorial models were compared using the DeLong
method.
After having assessed the magnitude of the association (logistic regression)
and the discrimination value (AUROC) of the aforementioned parameters, we
performed another statistical analysis to increase the robustness of our
findings. Classification and regression tree (CRT) analysis is a tree-building
technique used to classify patients into various risk categories, and it is ideal to
generate clinical decision rules.34 High sensitivity is an important feature for a
triage tool to ensure safety. We therefore performed the analysis assigning the
cost of misclassifying intubation or death as 10 times greater than the cost of
misclassifying other patients as described.20 The CRTanalysis was performed
with all vital signs, clinical severity scores, and biomarkers as continuous vari-
ables to let the software decide on the optimal variables combination and best
cutoffs. We decided on the following settings: minimum of 10 cases for parent
node and 5 for child node, pruning to reduce overfitting, and maximum levels
of 2 for tree depth. All analyses were performed with STATA (version 15.0,
Stata Corp, College Station, Tex), RCore Team (2019), and IBMSPSS version
26 (IBM Corporation, Armonk, NY).Consent for publication
All included patients signed an informed consent form.Ethics approval
The Swiss Ethics Committee of the canton of Vaud (CER-VD 2019-02283)
and the University Health Network – Toronto General Hospital (20-5442)
gave ethical approval.RESULTS
Demographics and clinical and laboratory findings
associated with 30-day COVID-19 severity
Among 165 patients prospectively included in the lower
respiratory tract infection cohort, 76 patients were real-time
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sample for analysis (see Fig E1 in this article’s Online Repository
at www.jacionline.org). Patients’ 30-day outcomes were as
follow: 24 (32%) outpatients or patients hospitalized without ox-
ygen requirement (17 outpatients, 7 hospitalized without oxygen
requirement), 35 (46%) hospitalized with oxygen requirement, 17
(22%) intubated and/or dead (5 intubated, 7 deaths without previ-
ous intubation, 5 intubatedwho died). Seven-day intubation/death
outcome differed by 2 patients compared with 30-day outcome.
These 2 patients died 8 and 9 days after inclusion. The same num-
ber of patients required oxygen 7 and 30 days after inclusion;
therefore, we present the 30-day oxygen requirement data.
After their initial consultation in ED, 20 patients were dis-
charged home. Three of these subsequently required a secondary
hospitalization for oxygen supplementation after a median of 2.6
days (interquartile range, 2.4-3.0). Among intubated patients, 1
was intubated shortly after enrollment and 9 were intubated later
after a median of 2.0 days (interquartile range, 2.0-3.0). Twelve
patients died after a median of 8.0 days (interquartile range, 2.8-
10.3).
Table I presents patient demographics, clinical characteristics,
and laboratory results. Although sex distribution, prevalence of
comorbidities, and duration of symptoms were similar between
the 3 severity groups, patients in the intubation/mortality group
were significantly older than the other participants. Respiratory
rate, oxygen saturation, qSOFA, and CRB-65 were
associated with 30-day intubation/mortality. Leukocyte count
and creatininewere significantly lower in patients without oxygen
requirement.Immune and endothelial activation mediators are
associated with 30-day COVID-19 severity
After correction for multiple comparisons, plasma concentra-
tions of the immune activation markers, IL-6 and sTREM-1, were
significantly higher between groups of increasing severity (Fig 1).
CRP was significantly different between the 2 extreme patient
groups, that is, those without oxygen requirement and those
who were intubated/died. The concentration of the endothelial
activation marker Ang-2 was significantly higher in ED patients
at presentation who subsequently were intubated/died within 30
days of enrollment. IL-8 was significantly lower in patients who
did not require oxygen.Vital signs, clinical severity scores, and biomarkers
predict 30-day intubation/mortality and oxygen
requirement
Of clinical signs, respiratory rate and oxygen saturation in the
ED displayed the best predictive accuracy (AUROC, 0.77, 95%
CI, 0.64-0.89, and AUROC, 0.78, 95% CI, 0.66-0.89, respec-
tively) for 30-day intubation/mortality. Severity scores (qSOFA
and CRB-65) did not perform better than respiratory rate or
oxygen saturation alone (Table II). sTREM-1 and IL-6 measured
in the ED were the best predictive markers for 30-day intubation/
mortality (AUROC, 0.86, 95% CI, 0.77-0.95, and AUROC, 0.80,
95% CI, 0.68-0.92, respectively); however, these were not signif-
icantly better than IL-8, Ang-2, or CRP, which all demonstrated
an acceptable prognostic value (AUROC, >0.70) (Fig 2, A).
No vital signs or clinical severity scores determined in the
ED displayed good predictive accuracy for subsequent oxygenrequirement (AUROC, <0.80) (Table II). The need for 30-day
oxygen supplementation was best predicted by IL-6 (AUROC,
0.84; 95% CI, 0.75-0.94) and IL-8 (AUROC, 0.82; 95% CI,
0.72-0.92) (Fig 2, B). sTREM-1 and CRP showed an acceptable
performance, which was not statistically lower than that of
IL-6. Ang-2 performed significantly worse than IL-6, IL-8, and
sTREM-1 (P < .005).Biomarkers of immune and endothelial dysfunction
improve the predictive accuracy of validated clinical
scores and vital signs
Combinations of biomarkers from similar or different patho-
physiological pathways associated with severe infections may
further improve the prognostic accuracy. However, we tested all
biomarker combinations and no combination improved predictive
accuracy over single markers.
In previous reports, combination of clinical signs or validated
clinical scores with biomarkers improved prognostic accuracy
when compared with clinical features alone.20,35 Therefore, we
combined clinical parameters with sTREM-1 and IL-6, the top
predicting biomarkers (AUROC >_ 0.80) of 30-day intubation/
mortality (Table II). The combination of respiratory rate with
sTREM-1 performed significantly better than the respiratory
rate alone (P 5 .024), but not better than sTREM-1 alone. We
found similar results when combining clinical scores and
sTREM-1 (Table II).
Multivariate analysis of combination of biomarkers and vital
signs to predict oxygen requirement are presented in Table E1
in this article’s Online Repository at www.jacionline.org.
Combining respiratory rate with IL-6 or IL-8 significantly
improved the predictive value of the model when compared
with respiratory rate only. Similarly, the predictive value of
CRB-65 and qSOFA for oxygen requirement was significantly
improved by a combination with IL-6 or IL-8. No combination
performed better than IL-6 or IL-8 alone.
To summarize, none of the tested combination improved
significantly the prediction accuracy compared with the bio-
markers alone.sTREM-1–based algorithms predict 30-day
intubation/mortality in patients with COVID-19
After having evaluated the magnitude of the association
between clinical signs, scores, biomarkers, and adverse outcome,
we performed a CRTanalysis to find optimal variables and cutoff
points suitable to generate simple algorithms. The resulting
classification tree represents visual decision making.
CRTanalysis including all biomarkers, vital signs, and clinical
scores identified a model including sTREM-1 only (Fig 3). To
allow for diagnostic stewardship, we performed the analysis
with sTREM-1, forcing respiratory rate and oxygen saturation,
the top predicting clinical signs, as the first variable in the algo-
rithm. Although the algorithms including respiratory rate or
sTREM-1 alone had a higher specificity, the algorithm including
respiratory rate and sTREM-1 exhibited the highest sensitivity
(94%) and the smallest negative likelihood ratio (0.10), allowing
a large decrease in the posttest probability of day-30 intubation/
death at first presentation to the ED (see Table E2 in this article’s
Online Repository at www.jacionline.org). The specificity of this
combined algorithmwas 61% and its positive likelihood ratio 2.3.
TABLE I. Characteristics of study participants at inclusion in the ED according to 30-day clinical outcomes
Characteristic All (n 5 76)
No oxygen
requirement (n 5 24)
Oxygen requirement (n 5 52)
P value*
No intubation/death
(n 5 35) Intubation/death (n 5 17)
Demographic
Sex: female, n (%) 43 (57) 12 (50) 22 (62) 9 (52) .584
Age (y), mean 6 SD 62 6 17 54 6 19 62 6 15 72 6 12 .002
Residence in nursing home, n (%) 8 (10) 0 (0) 4 (11) 4 (23) .057
Current smoker, n (%) 1 (1.3) 1 (4.0) 0 (0) 0 (0) .334
Comorbidities, n (%)
Any 55 (72) 18 (75) 26 (74) 11 (64) .724
Hypertension 36 (47) 9 (37) 19 (54) 8 (47) .447
Asthma 18 (23) 9 (37) 6 (17) 3 (17) .157
Diabetes 17 (22) 4 (16) 10 (28) 3 (17) .486
Obesity 19 (27) 6 (28) 8 (25) 5 (31) .894
Cardiovascular disease 10 (13) 2 (8.0) 3 (8.6) 5 (29) .080
Chronic obstructive pulmonary disease 3 (3.9) 1 (4.0) 0 (0) 2 (11) .124
Neurological disorder§ 11 (14) 2 (8.0) 3 (8.6) 6 (35) .022
Active cancer 3 (3.9) 0 (0) 2 (5.7) 1 (5.9) .486
Hepatitis or liver cirrhosis 1 (1.3) 0 (0) 1 (2.9) 0 (0) .552
Chronic renal failurek 3 (3.9) 0 (0) 2 (5.7) 1 (5.9) .486
Chronic inflammatory diseases{ 4 (5.3) 4 (16.7) 0 (0) 0 (0) .010
Symptoms
Duration (d), median (IQR) 7 (5.7-11) 7 (5-11) 7 (7-11) 8 (4-10) .905
History of fever, n (%) 62 (82) 18 (75) 28 (80) 16 (100) .105
Cough, n (%) 68 (90) 21 (87) 33 (94) 14 (87) .602
Dyspnea, n (%) 58 (76) 15 (62) 30 (86) 13 (76) .120
Vital signs at inclusion in ED
Glasgow Coma Scale score <15, n (%) 2 (2.7) 0 (0) 0 (0) 2 (12) .032
Temperature (8C), median (IQR) 37.0 (36.7-38.2) 37.1 (37.0-37.0) 37.6 (37.0-38.0) 38.0 (37.0-38.0) .102
Systolic BP (mm Hg), median (IQR) 133 (122-142) 133 (119-141) 133 (125-143) 135 (118-142) .889
Heart rate (bpm), median (IQR) 85 (77-95) 80 (75-85) 87 (80-100) 85 (82-98) .018
Respiratory rate (vpm), median (IQR) 23 (18-28) 20 (17-23) 23 (18-28) 26 (25-34) .001
Oxygen saturation, median (IQR) 96 (93-97) 96 (96-97) 95 (94-97) 93 (91-95) .001
Clinical scores at inclusion in ED
qSOFA >_ 2, n (%) 2 (2.7) 0 (0.0) 0 (0.0) 2 (12) .034
CRB-65 >_ 2, n (%) 9 (13) 0 (0.0) 3 (8.6) 6 (35) .003
Laboratory findings at inclusion in ED
Leukocyte count (G/L), median (IQR) 6.2 (4.8-8.0) 5.1 (4.4-6.0) 6.4 (5.4-7.5) 8.7 (5.7-10) .002
Hemoglobin (g/L), median (IQR) 139 (129-149) 145 (139-154) 136 (127-147) 135 (131-145) .053
Platelet count (G/L), median (IQR) 212 (160-288) 226 (163-274) 209 (158-293) 186 (158-275) .720
Creatinine (mmol/L), median (IQR) 91 (79-109) 91 (70-98) 89 (77-113) 105 (88-126) .034
Radiology
Infiltrate on chest radiograph, n (%) 54 (76) 10 (53) 29 (83) 15 (88) .018
Clinical outcome, n (%)
7-d intubation/death 15 (20)
30-d intubation/death 17 (22)
7-d oxygen requirement 52 (68)
30-d oxygen requirement 52 (68)
BMI, Body mass index; BP, blood pressure; bpm, beats per minute; CKD, chronic kidney disease; FiO2, fraction of inspired oxygen; IQR, interquartile range; vpm, ventilations per
minute.
Missing values: obesity 7, duration of symptoms 8, fever 1, cough 1, vital signs 5, blood cell count 1, chest radiograph 6, lung ultrasound 5, CRB-65 4, qSOFA 3.
*Differences between the 3 groups evaluated by 1-way ANOVA, Kruskal-Wallis, or x2, as appropriate.
BMI > 30 kg/m2.
Heart failure, coronary disease.
§Stroke, dementia, Parkinson.
kStage III-V according to CKD classification.
{Autoimmune or chronic inflammatory disease.
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not possible without overfitting the model.
Because it is also important to identify patients who
require immediate medical attention, we also assessed the
performance of this algorithm to predict 7-day intubation/death.
The sensitivity wasmaintained at 93%, the specificity at 59%, andthe negative and positive likelihood ratio were 0.17 and 2.3,
respectively.
Because we could use this triage tool to identify patients
requiring oxygen, we tested this algorithm to predict 7- and 30-
day oxygen requirement. Although it was highly specific (100%),
its sensitivity was low (25%) in this setting.
FIG 1. Plasma concentration of immune and endothelial dysfunction markers at inclusion in the ED
according to 30-day COVID-19 outcome. ns, Nonsignificant. Boxplot with median and interquartile range.
Concentrations reported in pg/mL except CRP in mg/L. P values were computed using the Wilcoxon-
Mann Whitney test and were adjusted for multiple comparisons using Bonferroni method. *P < .01;
**P < .001; ***P < .0001.
TABLE II. Prognostic accuracy of vital signs and clinical
scoring systems alone and in combination with top predicting




Clinical parameter (1) sTREM-1 (1) IL-6
Heart rate 0.58 (0.43-0.74) 0.85 (0.76-0.95)* 0.81 (0.69-0.92)*
Respiratory
rate
0.77 (0.64-0.89) 0.86 (0.59-0.89)* 0.85 (0.74-0.96)
Oxygen
saturation
0.78 (0.66-0.89) 0.86 (0.77-0.95)* 0.86 (0.76-0.96)
qSOFA 0.71 (0.60-0.82) 0.85 (0.74-0.96)* 0.85 (0.74-0.96)
CRB-65 0.75 (0.66-0.88) 0.88 (0.79-0.98)* 0.87 (0.77-0.97)*
sTREM-1 0.86 (0.77-0.95)
IL-6 0.80 (0.68-0.92)
Missing values: CRB-65 4, qSOFA 3, Heart rate 1, Respiratory rate 1.
AUROCs were calculated from the predictive probabilities of logistic regression
models to 30-d mortality/intubation. AUROC of clinical parameters alone and
combined with sTREM-1 or IL-6 are presented. Differences in AUROCs were
assessed using the DeLong method.
*P < .05 comparing the clinical parameter AUROC vs the combined clinical parameter
with sTREM-1 or IL-6 AUROC.
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requirement in patients with COVID-19
The CRT analysis performed with all clinical signs, severity
scores, and biomarkers to predict 30-day oxygen requirement
selected IL-6 only (with a cutoff <_15.1 pg/mL vs >15.1 pg/
mL). This algorithm had a sensitivity of 98%, specificity of 50,
a negative likelihood ratio at 0.04, and a positive likelihood
ratio at 2.0 (see Fig E2 and Table E2 in this article’s Online
Repository at www.jacionline.org). To allow for diagnostic
stewardship, we performed the analysis with IL-6, forcing res-
piratory rate and oxygen saturation, as the first variable in the
algorithm. However, it was not possible without overfitting the
model.Because we could also use this triage tool to identify patients at
high risk of poor outcomes, we tested this algorithm to predict 7-
and 30-day intubation/death. It had an excellent sensitivity
(100%) but a poor specificity (21%) for 7-day intubation/death
and showed a similar performance for 30-day intubation/death
(sensitivity at 100% and specificity at 22%).DISCUSSION
The development of an accurate triage tool to aid clinical
decision making in the ED is critical for the early and rapid
recognition of patients with COVID-19 at risk for deterioration
and to optimize resource allocation in the context of a global
pandemic.10 Immune and endothelial activation contribute to
immunopathology, microvascular dysfunction, and a procoagu-
lable state and have been proposed as pathophysiological
pathways leading to adverse outcomes associated with
COVID-19.23,25,36-38 In this prospective cohort of SARS-CoV-2–
infected patients, we test the hypothesis that measuring markers
of these pathways at first presentation to the ED may enable early
triage and risk stratification of patients with COVID-19. We
report that sTREM-1 and IL-6, when measured at presentation
to the ED, have good predictive accuracy for 30-day clinical dete-
rioration and 30-day oxygen requirement, respectively. No com-
bination of biomarkers and clinical data performed better than
single biomarkers.
Among the biomarkers of immune and endothelial dysfunc-
tion tested, sTREM-1 had the best prognostic accuracy for day-
30 intubation/death. CRP elevation has been previously associ-
ated with severe COVID-19 and has been proposed as a
biomarker to predict COVID-19 severity alone or combined
with other variables.11,39-42 In our study, the predictive accuracy
of CRP was less than that of sTREM-1. Respiratory rate and ox-
ygen saturation measured at the EDwere the best predictive vital
sign and performed as well as clinical scores. Adding sTREM-1
significantly improved the predictive accuracy of respiratory
FIG 3. CRT analysis algorithms to predict day-30 intubation/mortality in COVID-19 at ED. The algorithms
were generated for (A) respiratory rate, (B) sTREM-1, and (C) respiratory rate and sTREM-1. CRT analysis
including all biomarkers, vital signs, and clinical scores identified the model including sTREM-1 only (Fig
3, B). CRT was then performed with respiratory rate only (Fig 3, A) and with a combination of respiratory
rate and sTREM-1 (Fig 3, C). For all algorithms, the cost of misclassifying a patient who was intubated or
died was designated as 10 times the cost of misclassifying a patient who survived without intubation. Cutoff
points selected by the CRT analysis are shown between the parent and child nodes. The outcome prediction
of the model is indicated below each terminal node.
FIG 2. Prognostic accuracy of host biomarkers measured at ED in patients with COVID-19 for (A) 30-day
mortality and/or intubation and (B) 30-day oxygen requirement. Nonparametric ROC curves were generated
and AUROCs were plotted to illustrate the ability of these markers to discriminate between patient groups.
Each AUROC was compared with other using the DeLong method. AUROCs for the outcome of each
biomarker are presented to the right of its respective forest plot, with 95% CIs in parentheses. *Ang-2 per-
formed significantly worse than sTREM-1, IL-6, and IL-8 (P < .05) to predict 30-day oxygen requirement. No
other comparison reached a statistically significant difference (P < .05).
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on respiratory rate (cutoff point at 24/min) and sTREM-1 (cutoff
point at 689 pg/mL) with an excellent predictive accuracy for
ruling out 7-day and 30-day risk of respiratory failure or death.
Ultimately, the availability and use of sTREM-1 rapid tests such
as the ‘‘near patient’’ 1 hour test used in this study,32 or point-of-care test versions suitable for low-income settings, might enable
the early recognition of patients in EDs or outpatient clinics at
risk of adverse outcomes with a high sensitivity. However, the
performance of this algorithm to identify patients with a lower
level of severity (those requiring oxygen) was not optimal
with a low sensitivity. Our data do not support the use of a
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requirement.
To our knowledge, this is the first study evaluating sTREM-1 in
the context of COVID-19 risk stratification. Our results warrant
further evaluation of sTREM-1 as an early COVID-19 triage tool
in the ED. TREM-1 is a receptor from the immunoglobulin
superfamily expressed both on blood neutrophils and on mature
monocytes/macrophages. It participates in signaling pathways
that amplify inflammatory responses inducing release of proin-
flammatory mediators such as TNF-a and IL-1b.18,21,43 Its solu-
ble counterpart, sTREM-1, results from the proteolytic cleavage
of membrane-anchored TREM-1 by metalloproteinases, after
stimulation of TREM-1 by proinflammatory molecules, such as
LPS and activation of Toll-like receptor 4.17,44,45 The mononu-
clear phagocyte system is likely implicated in severe COVID-
19 via, among others, the Toll-like receptor 4-tumor necrosis fac-
tor receptor-associated factor 6 (TRAF6)-nuclear factor kappa
B (NF-kB) pathway.19 Therefore, activation of the TREM-1
signaling pathway on monocytes/macrophages might contribute
to the development of a cytokine storm in the context of
COVID-19, and justify the use of the sTREM-1 concentration
to predict adverse outcome. However, given our limited sample
size, our findings warrant further validation studies. Previous re-
ports showed that sTREM-1 has a high prognostic accuracy for
adverse outcomes in febrile patients and in those presenting
with septic shock, and is superior to widely used biomarkers
including CRP and procalcitonin.21 An sTREM-1–based algo-
rithm developed to predict all-cause mortality in febrile patients
attending ED in an African low-resource setting showed a high
prognostic performance and was superior to CRP and procalcito-
nin.20 These data suggest that sTREM-1 could be used as an early
prognostic tool in the ED to support safe triage of patients with a
broad spectrum of infections.
The elevation of inflammatory cytokines such as IL-6 has
previously been reported in association with severe
COVID-19.12,14,15,46 Here, we show that IL-6 was the best predic-
tor of oxygen requirement in patients with COVID-19. The com-
bination of respiratory rate with IL-6 performed significantly
better than respiratory rate alone. An IL-6–based algorithm
(IL-6 cutoff point of 15.1 pg/mL) had a high sensitivity and low
negative likelihood ratio, allowing safe outpatient management
in selected patients. This algorithm would have identified at their
first ED visit the 3 patients who were secondary admitted for ox-
ygen supplementation, as well as 4 of 7 (57%) patients who were
admitted but never received oxygen supplementation. Measure-
ment of IL-6 with a rapid point-of-care test at the ED might sup-
port clinicians in their decision of patients’ hospital admission.
Our study had limitations including a small number of
cases, leading to a lack of power to show significant differences
between the prognostic accuracy of tested biomarkers, as well as
combinations of biomarkers and vital signs versus biomarkers
alone. Another limitation is the lack of external validation of our
algorithms in another cohort. We used a 30-day outcome to avoid
missing late events. Day-30 outcomes might represent late
complications unrelated to the viral infection. However, in-
tubations or deaths all occurred within the first 9 days of inclusion
and oxygen requirement during the first 7 days. In our cohort, we
conclude that 30-day outcome represents early complications
related to the viral disease. Indeed, most adverse outcomes
occurred quickly after hospitalization as reported in previous
studies.12,47Nevertheless, our data support sTREM-1 and IL-6 as potential
candidates for point-of-care test, which could be used as a triage
tool at presentation to predict disease severity in COVID-19.
sTREM-1– or IL-6–based algorithms are complementary
because they identify patients with a differing clinical COVID-
19 severity. One outcome might be a preferred triage tool to
decide on patient admission early in the outbreak, whereas the
other might be more appropriate to prevent overwhelming
health care systems. Indeed, in case of scarce resources, we
prioritize admission of patients at a higher risk of severe outcome
(intubation/death: RR/sTREM-1 algorithm), whereas less severe
patients who will subsequently only require oxygen (IL-6
algorithm) could be managed as outpatients with oxygen supple-
mentation to free up hospital beds. Medical resource allocation is
a dynamic process affected by demands on health systems. Such
increased demand lead to a shortage of medical supplies and
induce the need of optimal resource allocation.5 However, larger
studies are needed to differentiate which model is superior for ED
triage.
In this study, both algorithms were very sensitive, with a low
negative likelihood ratio ensuring safe management of patients.
Ultimately biomarker-based algorithms such as these could
enhance clinical decision making and resource allocation; how-
ever, this will require further prospective trials to confirm their
risk stratification performance in actual practice.
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Clinical implications: Our findings suggest that sTREM-1 and
IL-6 concentrations measured at presentation to the ED can
be used as triage tools in patients with COVID-19 to decide on
outpatient management or close monitoring.REFERENCES
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FIG E1. Flowchart of study participants.
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FIG E2. CRT analysis algorithms to predict day-30 oxygen requirement in COVID-19 at ED. CRT analysis
including all biomarkers identified the model including IL-6 only. The cost of misclassifying a patient who
required oxygenwas designated as 10 times the cost ofmisclassifying a patient who did not require oxygen.
Cutoff point selected by the CRT analysis is shown between the parent and child nodes. The outcome
prediction of the model is indicated below each terminal node.
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TABLE E1. Prognostic accuracy of vital signs and clinical
scoring systems alone and in combination with top predicting




Clinical parameter (1) IL-6 (1) IL-8
Heart rate 0.70 (0.59-0.83) 0.87 (0.78-0.97)* 0.86 (0.77-0.94)*
Respiratory
rate
0.72 (0.59-0.84) 0.85 (0.76-0.95)* 0.85 (0.76-0.94)*
qSOFA 0.66 (0.54- 0.78) 0.84 (0.74-0.94)* 0.85 (0.75-0.94)*
CRB-65 0.67 (0.55-0.78) 0.83 (0.72-0.93)* 0.83 (0.73-0.92)*
IL-6 0.84 (0.75-0.94)
IL-8 0.82 (0.72-0.92)
Missing values: CRB-65 4, qSOFA 3, Heart rate 1, Respiratory rate 1.
AUROCs were calculated from the predictive probabilities of logistic regression
models to 30-d oxygen requirement. Clinical parameter AUROC alone and combined
with IL-6 or IL-8 are presented. Differences in AUROCs were assessed using the
DeLong method.
*P < .05 comparing the clinical parameter AUROC vs the combined clinical parameter
with IL-6 or IL-8 AUROC.
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TABLE E2. Prognostic performance characteristics of CRT models for 7- and 30-day intubation/mortality and 30-day oxygen
requirement outcomes in patients with COVID-19
Performance





sTREM-1 RR sTREM-1 1 RR sTREM-1 1 RR IL-6
Sensitivity 83% 77% 94% 93% 98%
Specificity 81% 76% 61% 59% 50%
Positive predictive value 56% 48% 41% 36% 81%
Negative predictive value 94% 92% 97% 97% 92%
LR1 4.4 3.2 2.4 2.3 2.0
LR2 0.21 0.30 0.10 0.17 0.04
LR1, Positive likelihood ratio; LR2, negative likelihood ratio; RR, respiratory rate.
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